Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia

Neurotherapeutics

Volumn 6, Issue 1, 2009, Pages 78-85

  Kim, Dennis H ^a   Maneen, Matthew J ^a   Stahl, Stephen M ^b  

^a Arbor Scientia   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotics; glutamatergic neurotransmission; intramolecular; negative; polypharmacy; receptors; symptoms

Indexed keywords

ALANINE; ALPHA ADRENERGIC RECEPTOR; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; CYCLOSERINE; DOPAMINE 2 RECEPTOR; GLYCINE; GLYCINE RECEPTOR AGONIST; HISTAMINE H1 RECEPTOR; KETAMINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; MUSCARINIC M1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORCLOZAPINE; OPC 4293; PHENCYCLIDINE; RISPERIDONE; SARCOSINE; SERINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BLURRED VISION; BRAIN NERVE CELL; BRAIN REGION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MAJOR DEPRESSION; MANIA; NAUSEA AND VOMITING; NEGATIVE SYNDROME; NONHUMAN; ORTHOSTATIC HYPOTENSION; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GLYCINE AGENTS; HUMANS; RECEPTORS, DOPAMINE D2; RECEPTORS, GLUTAMATE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 57749100301     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.10.020     Document Type: Article

References (55)

1. Kirkpatrick B., Fenton W.S., Carpenter Jr. W.T., and Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32 (2006) 214-219
2. Stahl S.M. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. 3rd ed (2008), Cambridge University Press, New York
3. Strange P.G. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol Sci 29 (2008) 314-321
4. 2 receptor explain the action of atypical antipsychotics?. A new hypothesis. Am J Psychiatry 158 (2001) 360-369
5. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10 (2005) 79-104
6. Meltzer H.Y. What's atypical about atypical antipsychotic drugs?. Curr Opin Pharmacol 4 (2004) 53-57
7. Schmidt A.W., Lebel L.A., Howard Jr. H.R., and Zorn S.H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425 (2001) 197-201
8. Stahl S.M. Do dopamine partial agonists have partial efficacy as antipsychotics?. CNS Spectr 13 (2008) 279-282
9. 2 receptors. J Pharmacol Exp Ther 302 (2002) 381-389
10. Carlsson A., Waters N., and Carlsson M.L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol Psychiatry 46 (1999) 1388-1395
11. Lawler C.P., Prioleau C., Lewis M.M., et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 (1999) 612-627
12. 1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164 (2007) 1411-1417
13. Berman R.M., Marcus R.N., Swanink R., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68 (2007) 843-853
14. Thase M.E., Jonas A., Khan A., et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 28 (2008) 13-20
15. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76 (2001) 1521-1531
16. 1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 14 (1996) 35-46
17. Sumiyoshi T., Matsui M., Nohara S., et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158 (2001) 1722-1725
18. 1A receptors on human explicit memory. Am J Psychiatry 160 (2003) 334-340
19. Gray J.A., and Roth B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33 (2007) 1100-1119
20. Alex K.D., and Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113 (2007) 296-320
21. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37 (1998) 953-955
22. Gray J.A., and Roth B.L. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12 (2007) 904-922
23. 2C receptors. Synapse 55 (2005) 242-251
24. 2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 64 (2008) 477-482
25. 2C receptor antagonist. Br J Pharmacol 126 (1999) 572-574
26. Stahl S.M. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol 10 (2007) 575-578
27. 7) positively linked to adenylate cyclase. J Biol Chem 268 (1993) 23422-23426
28. 7) implicated in the regulation of mammalian circadian rhythms. Neuron 11 (1993) 449-458
29. 7) activating cAMP formation. Proc Natl Acad Sci USA 90 (1993) 8547-8551
30. 7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology 21 (1999) 352-367
31. Roth B.L., Craigo S.C., Choudhary M.S., et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268 (1994) 1403-1410
32. 7 receptor antagonist, modulates REM sleep in rats. Br J Pharmacol 139 (2003) 705-714
33. 7 receptor. Neuropharmacology 44 (2003) 1031-1037
34. 7 receptor antagonist. Br J Pharmacol 130 (2000) 539-548
35. 7 receptor knockout mice. Proc Natl Acad Sci USA 100 (2003) 1375-1380
36. Manuel-Apolinar L., and Meneses A. 8-OH-DPAT facilitated memory consolidation and increased hippocampal and cortical cAMP production. Behav Brain Res 148 (2004) 179-184
37. 7 receptors show specific impairments in contextual learning. Eur J Neurosci 19 (2004) 1913-1922
38. Jorgensen H., Riis M., Knigge U., Kjaer A., and Warberg J. Serotonin receptors involved in vasopressin and oxytocin secretion. J Neuroendocrinol 15 (2003) 242-249
39. 7 receptor. Brain Res Dev Brain Res 139 (2002) 199-203
40. Stahl S.M. Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr 12 (2007) 265-268
41. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20 (1999) 106-118
42. Olney J.W., Newcomer J.W., and Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33 (1999) 523-533
43. Moghaddam B., and Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281 (1998) 1349-1352
44. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9 (2004) 984-997
45. Johnson J.W., and Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325 (1987) 529-531
46. Mothet J.P., Parent A.T., Wolosker H., et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 97 (2000) 4926-4931
47. Goff D.C., Herz L., Posever T., et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 179 (2005) 144-150
48. Heresco-Levy U., and Javitt D.C. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 66 (2004) 89-96
49. Tsai G.E., Yang P., Chang Y.C., and Chong M.Y. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 59 (2006) 230-234
50. Javitt D.C. Is the glycine site half saturated or half unsaturated?. Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 19 (2006) 151-157
51. van Berckel B.N., Evenblij C.N., van Loon B.J., et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21 (1999) 203-210
52. Bergeron R., Meyer T.M., Coyle J.T., and Greene R.W. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 95 (1998) 15730-15734
53. Stahl S.M. Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. CNS Spectr 12 (2007) 423-427
54. 3 partial agonist. J Pharmacol Exp Ther 315 (2005) 1278-1287
55. Sur C., Mallorga P.J., Wittmann M., et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100 (2003) 13674-13679